Pioglitazone 30 mg (Generic)

Product Overview

Pioglitazone 30 mg is a generic oral antidiabetic produced by USV Pvt. Ltd. Each tablet delivers 30 mg of pioglitazone, a thiazolidinedione that improves insulin sensitivity. The medication is supplied in strips containing 10 tablets, with pack options of 30, 60, or 90 tablets to suit various treatment lengths. It is indicated for type 2 diabetes mellitus as an adjunct to diet and exercise. The film‑coated tablets are taken once daily, and orders typically ship within 6 to 15 days from certified manufacturing facilities. The product meets international quality standards and is stored under controlled conditions to preserve potency. Patients should keep the tablets in a dry place away from direct sunlight. Always verify the expiration date before use.

What is Pioglitazone

Pioglitazone belongs to the thiazolidinedione class and acts as a selective agonist of peroxisome proliferator‑activated receptor‑gamma (PPAR γ). When bound to this nuclear receptor, it alters transcription of genes that increase glucose uptake in adipose tissue, muscle, and the liver while decreasing hepatic glucose production. This mechanism enhances insulin sensitivity without stimulating pancreatic insulin release, which lowers the likelihood of hypoglycemia when used alone. The drug’s effect develops gradually over several weeks as insulin‑sensitive pathways are up‑regulated. Clinical studies have shown that activation of PPAR‑γ improves lipid profiles by modestly lowering triglycerides and raising HDL cholesterol, contributing to overall metabolic benefit. These effects support its use as part of a comprehensive diabetes management plan.

Uses and Benefits

The primary therapeutic use of pioglitazone 30 mg is to improve glycemic control in adults with type 2 diabetes when lifestyle modifications alone are insufficient. In clinical trials, patients experienced a reduction in HbA1c of approximately 0.5 % to 1 % after 12 weeks of therapy. Beyond glucose lowering, pioglitazone has demonstrated modest improvements in cardiovascular risk markers, such as reduced triglyceride levels and increased HDL cholesterol. Some data suggest a potential delay in the progression of diabetic complications, although long‑term outcomes require further investigation. The medication is therefore prescribed as part of a broader strategy that includes diet, exercise, and regular monitoring of blood glucose. Patients are advised to undergo periodic assessments of kidney function and bone health to ensure safe use.

How It Works

The mechanism of action of pioglitazone centers on activation of PPAR γ receptors inside target cells. This activation triggers a cascade of gene expression that promotes fatty‑acid storage and enhances glucose transport in muscle and adipose tissue. Consequently, insulin sensitivity improves, leading to lower fasting glucose and reduced hepatic glucose output. The drug does not cause insulin secretion, which distinguishes it from sulfonylureas and reduces the risk of hypoglycemia. The therapeutic effect accumulates over several weeks as the transcriptional changes become established, making it a useful option for long‑term glycemic management when combined with appropriate diet and exercise. Regular monitoring of blood glucose levels helps clinicians assess the incremental benefit of therapy through consistent daily dosing.

Dosage Guidelines

Adults initiating pioglitazone therapy typically start with a 15 mg tablet taken once daily, with a possible increase to 30 mg once daily based on glycemic response and tolerability. The maximum recommended daily dose is 45 mg, which may be administered as a single 45 mg tablet or divided into 15 mg twice daily. For patients with moderate renal impairment (eGFR 30–59 mL/min/1.73 m²), the starting dose should be limited to 15 mg daily, and dose escalation should be done cautiously. Pioglitazone can be taken with or without food, but consistent timing helps maintain steady plasma concentrations. Patients should be reminded not to exceed the prescribed dose and to consult their healthcare provider before making any adjustments. Routine laboratory tests, including liver enzymes and kidney function, are recommended every 3–6 months to monitor safety.

Side Effects

Common adverse effects of pioglitazone include weight gain, peripheral edema, and occasional mild hypoglycemia when used together with insulin or sulfonylureas (see Drugs.com). Patients may also experience headache, sinus discomfort, or muscle aches. More serious concerns involve an increased risk of bone fractures, particularly in women, and a potential elevation in liver enzymes indicating hepatotoxicity; regular liver function testing is advised. Long‑term epidemiological studies have identified a modest rise in bladder cancer incidence, leading to caution in patients with a prior history of this disease. Although rare, severe allergic reactions such as rash or swelling require immediate medical attention. Awareness of these possibilities enables timely intervention and dose adjustment if necessary. Patients should report any sudden swelling, shortness of breath, or changes in urination to their physician promptly.

Warnings and Precautions

Pioglitazone is contraindicated in individuals with type 1 diabetes, a history of bladder cancer, or known hypersensitivity to the drug. It should not be prescribed to patients with New York Heart Association (NYHA) class III or IV heart failure, as it can exacerbate fluid retention. Caution is recommended for those with hepatic disease, osteoporosis, or a predisposition to cardiac events. Concomitant use with drugs that induce hepatic enzymes, such as rifampin, may diminish its efficacy. Pregnant or breastfeeding women should avoid pioglitazone unless the expected benefit outweighs the potential risk. Healthcare providers must review a patient’s complete medication list to avoid interactions with medications that affect liver enzymes or glucose control. Regular monitoring of weight, blood pressure, and laboratory values supports safe long‑term use. Patients should contact their clinician if they notice rapid weight gain or swelling.

FAQs